Literature DB >> 32273408

Catrina M Loucks1, Gabriella Groeneweg2, Carl Roy3, David K Lee4, Michael J Rieder5, Denis Lebel6, Shinya Ito7, Colin J Ross8, Bruce C Carleton9.   

Abstract

Entities:  

Year:  2020        PMID： 32273408      PMCID： PMC7145132     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  19 in total

1.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.

Authors:  M V Relling; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

2.  Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother.

Authors:  Gideon Koren; James Cairns; David Chitayat; Andrea Gaedigk; Steven J Leeder
Journal:  Lancet       Date:  2006-08-19       Impact factor: 79.321

3.  Pharmacogenetics: from bench to byte.

Authors:  J J Swen; I Wilting; A L de Goede; L Grandia; H Mulder; D J Touw; A de Boer; J M H Conemans; T C G Egberts; O H Klungel; R Koopmans; J van der Weide; B Wilffert; H-J Guchelaar; V H M Deneer
Journal:  Clin Pharmacol Ther       Date:  2008-02-06       Impact factor: 6.875

4.  Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy.

Authors:  Parvaz Madadi; Ursula Amstutz; Michael Rieder; Shinya Ito; Vincent Fung; Soomi Hwang; Jacques Turgeon; Veronique Michaud; Gideon Koren; Bruce C Carleton
Journal:  J Popul Ther Clin Pharmacol       Date:  2013-11-06

5.  Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years.

Authors:  Anne Andermann; Ingeborg Blancquaert; Sylvie Beauchamp; Véronique Déry
Journal:  Bull World Health Organ       Date:  2008-04       Impact factor: 9.408

6.  An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines.

Authors:  Francois Dionne; Folefac Aminkeng; Amit P Bhavsar; Gabriella Groeneweg; Anne Smith; Henk Visscher; Shahrad Rod Rassekh; Colin Ross; Bruce Carleton
Journal:  Pediatr Blood Cancer       Date:  2017-12-22       Impact factor: 3.167

7.  Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.

Authors:  Henk Visscher; Colin J D Ross; S Rod Rassekh; Amina Barhdadi; Marie-Pierre Dubé; Hesham Al-Saloos; George S Sandor; Huib N Caron; Elvira C van Dalen; Leontien C Kremer; Helena J van der Pal; Andrew M K Brown; Paul C Rogers; Michael S Phillips; Michael J Rieder; Bruce C Carleton; Michael R Hayden
Journal:  J Clin Oncol       Date:  2011-09-06       Impact factor: 44.544

Review 8.  Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.

Authors:  Folefac Aminkeng; Colin J D Ross; Shahrad R Rassekh; Soomi Hwang; Michael J Rieder; Amit P Bhavsar; Anne Smith; Shubhayan Sanatani; Karen A Gelmon; Daniel Bernstein; Michael R Hayden; Ursula Amstutz; Bruce C Carleton
Journal:  Br J Clin Pharmacol       Date:  2016-06-30       Impact factor: 4.335

9.  Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.

Authors:  Colin J D Ross; Hagit Katzov-Eckert; Marie-Pierre Dubé; Beth Brooks; S Rod Rassekh; Amina Barhdadi; Yassamin Feroz-Zada; Henk Visscher; Andrew M K Brown; Michael J Rieder; Paul C Rogers; Michael S Phillips; Bruce C Carleton; Michael R Hayden
Journal:  Nat Genet       Date:  2009-11-08       Impact factor: 38.330

10.  A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.

Authors:  Folefac Aminkeng; Amit P Bhavsar; Henk Visscher; Shahrad R Rassekh; Yuling Li; Jong W Lee; Liam R Brunham; Huib N Caron; Elvira C van Dalen; Leontien C Kremer; Helena J van der Pal; Ursula Amstutz; Michael J Rieder; Daniel Bernstein; Bruce C Carleton; Michael R Hayden; Colin J D Ross
Journal:  Nat Genet       Date:  2015-08-03       Impact factor: 38.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.